# Lipid accumulation product is a predictor of non-alcoholic fatty liver disease in childhood obesity

#### Bahar Özcabı<sup>1</sup>, Salih Demirhan<sup>2</sup>, Mesut Akyol<sup>3</sup>, Hatice Öztürkmen Akay<sup>4</sup>, Ayla Güven<sup>1</sup>

<sup>1</sup> Health Science University Medical Faculty Zeynep Kamil Maternity and Children's Diseases Research and Training Hospital Division of Pediatric Endocrinology <sup>2</sup> Health Science University Medical Faculty Zeynep Kamil Maternity and Children's Diseases Research and Training Hospital Department of Pediatrics J <sup>3</sup> Yıldırım Beyazıt University Medical Faculty Department of Biostatistics CC. Səğlik Bəkəl ürkiye Kamu Hastaneleri Ku İstanbul Anadolu Kuzey Kamu Hastaneleri Birliği

<sup>4</sup> Health Science University Medical Faculty Zeynep Kamil Maternity and Children's Diseases Research and Training Hospital Department of Radiology

## **OBJECTIVES:**

We aimed to evaluate the performance of lipid accumulation product (LAP) to predict non-alcoholic fatty liver disease (NAFLD) in

obese children.

### **METHODS:**

**Eighty obese chidren (39 girl) were included in this study (6-18 years).** 

Table 1: Clinical features and laboratory findings of patients with and without non-alcoholic fatty liver disease (NAFLD)

			Ctatistical	
NAFLD	No (n=39)	Yes (n=41)		


Height, weight, body mass index (BMI), waist circumference (WC), puberty	Variable
stage, blood pressure and biochemical values were obtained from the	Age, year
medical records. SDS and percentiles were calculated. LAP was calculated as	Gender
[WC (cm) - 58] x triglyceride concentration (mmol/L) in girls;	Puberty s
[WC (cm) - 65] x triglyceride concentration (mmol/L) in boys.	Stage 1 Stage 2 Stage 3
Other two variant LAP values were described according to 3% (minLAP) and	Stage 3 Stage 4 Stage 5
50% (adjLAP) of WC values previously considered for age and gender in	Weight Sl Height SD
childhood. The total cholesterol/HDL-cholesterol index (TC/HDL-C) was	BMI BMI SDS
calculated. NAFLD was showed by ultrasound. The AUC and appropriate	BMI % WC, cm
cutoff points for LAP, adjLAP and minLAP were calculated by ROC analysis.	Systolic T Diastolic
RESULTS:	Fasting gl Fasting in
	HOMA-IR

Variable		Mean±SD	<b>Mean±SD</b>	Statistical	р
		Median (IQR)	Median (IQR)	Analysis*	P
Age, year		11.1±2.8	<b>11.9±2.6</b>	t=1.299	0.198
Gender	Girl (n=38) Boy	25 (31.3%) 14 (17.4%)	13 (16.3%) 28 (35.0%)	c <sup>2</sup> =8.411	0.004
	(n=42)	I ( I / / 0)	20 (33.070)		
Puberty stage					
Stage 1 (n=22) Stage 2 (n=22) Stage 3 (n=12)		16 (20.0%)	6 (7.4%)	c <sup>2</sup> =12.633	0.013
		5 (6.3%)	17 (21.3%)		
		7 (8.8%)	5 (6.3%)		
Stage 4 (n=15) Stage 5 (n=9)		6 (7.4%) 5 (6.3%)	9 (11.2%) 4 (5.0%)		
Weight SDS		2.55 (0.90)	2.99 (1.21)	Z=2.691	0.007
-			0.97±1.37		
Height SDS		0.73±0.96		t=0.895	0.374
BMI		26.90 (6.19)	30.71(4.43)	Z=3.316	0.001
BMI SDS		2.38±0.48	2.76±0.59	t=3.108	0,003
BMI %		98.7 (1.7)	99.7 (1)	Z=3.124	0.002
WC, cm		89.7±13.3	98.8±10.5	t=3.399	0.001
Systolic TA, mmHg (n=28)		115.0 (14.3)	122.5 (10.0)	Z=3.241	0.001
Diastolic TA, mmH	lg (n=28)	<b>73</b> ±8	77±9	t=1.672	0.100
Fasting glucose, m	ng/dl	<b>90±8</b>	<b>89</b> ±7	t=0.756	0.452
Fasting insulin, ul	J/ml	12.70 (9.70)	17.40 (8.25)	Z=3.311	0.001
HOMA-IR		<b>2.93±1.5</b>	<b>4.01±1.54</b>	t=3.169	0.002
ALT, IU/L		17 (10)	28 (22)	Z=4.528	<0.001
AST, IU/L (n=30)		20 (6)	21 (9)	Z=1.103	0.285
Uric acid, mg/dl (n=77)		4.7 (1.3)	5.2 (1.5)	Z=2.821	0.005
Cholesterol, mg/dl		<b>163±34</b>	<b>170±26</b>	t=1.141	0.257
Triglyceride, mg/dl		91.0 (52.0)	114 (62)	Z=1.771	0.077
HDL-C, mg/dl (n=79)		45 (13)	47 (16)	Z=0.300	0.764
LDL-C, mg/dl (n=79)		94±28	101.3±19.5	t=1.302	0.197
Cholesterol/HDL-C, (n=79)		3.74 (0.91)	3.88 (1.41)	Z=1.595	0.111
LAP		30.4 (20.3)	42.8 (43.0)	Z=3.047	0.002
AdjLAP (%50)		32.1 (23.9)	43.3 (40.7)	Z=2.936	0.003
MinLAP (%3)		45.9 (23.9)	56 (48.5)	Z=2.666	0.008

with and without liver fat are summarized in the Table 1. LAP showed a positive and moderate correlation with puberty stage (rho=0.409; p<0.001), fasting insulin (rho=0.507; p<0.001), HOMA-IR (rho=0.470; p<0.001), uric acid (rho=0.522; p<0.001), TC/HDL-C (rho=0.494; p<0.001) and a weak negative correlation with HDL-C (rho=-3.833; p<0.001). Similar results were detected for minLAP and adjLAP. It was found that LAP values could be used to diagnose hepatosteatosis (AUC = 0.698; p = 0.002). Sensitivity and specificity values for LAP  $\geq$  42.70 cases were found as 53.7% and 84.6%, respectively (Figure 1). The cut-off points for LAP were AUC = 0.704; p = 0.033 in males and AUC = 0.693; p = 0.013 in pubertal. While the cutoff point for adjLAP  $\geq$  40.05 (AUC=0.691; p=0.003), sensitivity (58.5%) and

**Anthropometric measurements, biochemical values and indexes in patients** 





specificity (74.4%) were calculated. While the cutoff point for minLAP ≥

**53.47 (AUC=0.673;** p = 0.0083), sensitivity (56.1%) and specificity (76.9%)

were found. LAP exhibited a high diagnostic accuracy for identifying NAFLD

(AUC=0.698; p=0.002).

Figure 1: ROC curve of LAP, adjLAP and minLAP

## **CONCLUSIONS:**

LAP is a is a powerfull and easy tool to predict NAFLD in childhood and is correlated with TC/HDL-C and uric acid level. This is the

first study assessing the accuracy of LAP in childhood obesity.

